Highlights
- GAAP Revenue climbed 176.7% year over year to USD 253.7 million, giving an annualized run rate above USD 1 billion.
- Adjusted EBITDA rose to USD 42.7 million, though the Margin narrowed as lower-margin non-cannabis revenue joined the mix.
- Fourth-quarter guidance calls for revenue of USD 250 million to 265 million and adjusted EBITDA of USD 45 million to 48 million.
Vireo Growth Inc. (CN:VREO) delivered a step change in scale with its third-quarter results, released on Tuesday, as a run of acquisitions nearly tripled its revenue from a year earlier. The vertically integrated cannabis company, which now also operates an agricultural Supply business, said its annualized revenue run rate based on quarterly GAAP sales has passed the billion-dollar mark. Adjusted EBITDA rose substantially, though margins narrowed as the Business mix shifted and integration costs mounted.
Scale Arrives Through Acquisition
Reported revenue climbed to nearly three times its prior-year level. Cannabis revenue roughly doubled, while a non-cannabis segment that did not exist a year ago contributed more than a fifth of the total. Sequentially, revenue increased by about a fifth from the second quarter, with cannabis sales up by a low double-digit rate and non-cannabis sales rising by around two-thirds.
Because acquisitions distort year-over-year comparisons, Vireo also provided pro forma figures that assume recently completed Colorado and Nevada deals had closed at the start of the quarter. On that basis, cannabis revenue grew by a high single-digit percentage from the comparable pro forma period. Pro forma retail revenue rose modestly, which Chief Executive Officer John Mazarakis described as a proxy for same-store sales growth, while pro forma wholesale revenue increased by roughly half.
The non-cannabis segment deserves separate attention because it changes the character of the company. This agricultural supply business operates outside the licensed dispensary channel, and it runs at far lower margins than cannabis retail. It brings revenue Diversification and a lender relationship with a major Canadian bank, but it also dilutes consolidated margin percentages. Management signalled that this business is expected to decline sequentially in the fourth quarter, so headline revenue comparisons over the coming periods will partly reflect those swings rather than trends in cannabis Demand alone.
State-by-State Retail Performance
The geographic picture was varied. Pro forma retail revenue rose in Minnesota, Nevada, Utah, Missouri, New Mexico and Florida, with Minnesota and Florida showing particularly strong growth. Colorado, which became a larger part of the business through the recent acquisitions, posted a double-digit decline, and New York retail fell sharply. Maryland edged lower and California was flat.
Mazarakis linked the retail growth to local teams integrating acquired Assets and improving performance, a reflection of the company's decentralized operating model. He said that with an annualized revenue run rate exceeding a billion dollars, the company has established significant scale.
Margins Reflect a Changing Mix
GAAP gross margin improved slightly from the prior-year quarter but declined from the second quarter. Adjusted gross margin, which excludes Fair Value adjustments and non-cash product costs, fell markedly from a year ago, largely because the non-cannabis business carries a much thinner margin than cannabis. Even within cannabis, the adjusted gross margin eased by several percentage points.
Adjusted EBITDA grew by about two-thirds year over year and rose slightly from the second quarter, but the adjusted EBITDA margin compressed to the mid-teens from the high twenties a year earlier. The cannabis business generated the vast majority of adjusted EBITDA, while the agricultural supply business contributed a small amount at a low single-digit margin.
Below the operating line, the company recorded a net loss that was slightly narrower than a year earlier. Sales, general and administrative expenses more than doubled with the larger footprint, and transaction, integration and one-time costs rose sharply. Net interest expense and a sizeable income tax charge also weighed on results, a familiar pattern among United States operators listed among Canadian-listed cannabis stocks.
Funding the Expansion
Vireo ended the quarter with more than one hundred million dollars in cash including restricted cash, down from the start of the year after heavy Capital spending. Operating Cash Flow for the nine-month period turned positive compared with an outflow a year earlier. Total assets grew substantially with the acquisitions, and long-term Debt stood in the hundreds of millions of dollars. The company reported net debt, excluding convertible debt, of a little under two hundred million dollars.
Several financing moves shaped the balance sheet. The company repurchased subordinate voting shares under its normal course issuer bid during the quarter. It also has a five-year asset-based revolving Credit Facility with Bank of Montreal for the agricultural supply business. After quarter end, Vireo arranged a fixed-rate real estate term Loan from a United States commercial bank, secured by cultivation and production facilities in New York and Florida, and used part of the proceeds to refinance a higher-cost seller note. Replacing that expensive Acquisition financing with conventional bank debt at a lower fixed rate should reduce interest costs, and it signals growing access to mainstream lenders for a company operating in a sector that has historically faced constrained banking Options in the United States.
Florida Build-Out and the Planet 13 Merger
Florida featured prominently in the post-quarter updates. Vireo closed its FLUENT acquisition, adding more than thirty dispensaries in the state, and received federal Drug Enforcement Administration registrations for all of its state-licensed medical dispensaries there.
The pipeline remains full. Vireo has an all-stock Merger agreement with Planet 13 that is expected to expand its Nevada and Florida platforms and establish a presence in Illinois. The registration statement for that deal has been declared effective, and Planet 13 shareholders are scheduled to meet in early December. The company also has an agreement to acquire select Cannabist assets across Colorado, Illinois, Massachusetts and New Jersey, a joint venture interest tied to a Pennsylvania clinical registrant licence, and four definitive agreements to build a vertically integrated platform in Ohio. Once announced transactions close, Vireo expects to operate roughly two hundred and seventy dispensaries across fifteen states, compared with about two hundred and ten in ten states currently.
Quarterly Guidance in Place of an Annual Outlook
Rather than full-year targets, Vireo is issuing guidance one quarter at a time while acquisitions continue. For the fourth quarter, it expects revenue broadly in line with the third quarter and adjusted EBITDA slightly higher. That outlook includes FLUENT from its closing date, excludes pending deals and reflects an expected sequential decline in the non-cannabis business. For the first quarter of next year, guidance calls for higher revenue and adjusted EBITDA, incorporating a full quarter of FLUENT.
The company noted that pending acquisitions, had they closed before the start of each quarter, could add meaningful revenue and adjusted EBITDA on top of those ranges. Looking toward next year, Mazarakis pointed to the decentralized model, Leadership depth and capital allocation discipline as drivers of value. Key items to monitor include the Planet 13 Shareholder vote, closing of the Cannabist and Ohio transactions, margin trends as the agricultural business normalizes, and progress in reducing integration costs.






Please wait processing your request...